# A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

> **NCT06831058** · PHASE2 · RECRUITING · sponsor: **University of Minnesota** · enrollment: 15 (estimated)

## Conditions studied

- Immune-mediated Thrombotic Thrombocytopenic Purpura

## Interventions

- **DRUG:** efgartigimod

## Key facts

- **NCT ID:** NCT06831058
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2028-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06831058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06831058, "A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06831058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*